Direct medical cost of metformin and metformin-glimepiride in type 2 diabetes mellitus patients
DOI:
https://doi.org/10.12928/mf.v19i2.21588Keywords:
Cost Analysis, Type 2 DM, Metformin, Metformin-GlimepirideAbstract
Diabetes mellitus (DM) requires long-term therapy. Selection of the right therapy was very important to provide optimal results at an affordable cost. One of the main standards of oral antidiabetic therapy prescribed for type 2 DM (T2DM) is metformin, either alone or in combination therapy. The purpose of this study was to describe the direct medical costs in type 2 DM patients between metformin and metformin-glimepiride therapy. This research was an observational and descriptive. Demographic and clinical data were taken prospectively from the complete medical records of data patients with the main diagnosis of DM who fulfilled the inclusion criteria in the period January 2019–November 2020 at RSU Nene Mallomo Sidenreng Rappang, South Sulawesi and the two Public Health Centers namely Puskesmas Galur. II and Panjatan II Kulon Progo Yogyakarta. Cost data includes total medical costs from the hospital/ healthcare perspective (cost of drugs, doctor's services and checkups, fees for checking Fasting Blood Glucose/ Gula darah Puasa (GDP) and Blood Glucose Level While/ Gula Darah Sewaktu (GDS)) and total costs from the Badan Penyelenggara Jaminan Sosial (BPJS)/ payer perspective (INA-CBG's rates) were covered by insurance. The results showed that the average direct medical costs at the hospital and the two Public Health Centers respectively were metformin therapy in IDR (Indonesian Rupiah) namely IDR 120.736 and IDR 9.072,- and metformin-glimepiride therapy of IDR 126.298,- and IDR 18.634,-. It can be concluded that the average direct medical cost of metformin therapy is lower than metformin-glimepiride therapy.
References
Andayani, T.M. 2013. Farmakoekonomi: Prinsip dan Metodologi. Cetakan I. Yogyakarta: Bursa Ilmu Karangkajen.
Bina Pelayanan Kefarmasian. 2013. Pedoman Penerapan Kajian Farmakoekonomi. Kementrian Kesehatan Republik Indonesia. Jakarta.
BPJS Kesehatan. 2015. Peraturan Baddan Penyelenggara Jaminan Sosisal Kesehatan Nomor 2 Tahun 2015 Tentang Norma Penetapan Besaran Kapitasi dan Pembayaran Kapitasi Berbasis Pemenuhan Komitmen Pelayanan pada Fasilitas Kesehatan Tingkat Pertama. Jakarta: Badan Penyelenggara Jaminan Sosial Kesehatan.
Cho, N.H., Shaw, J.E., Karuranga, S., Huang, Y., da Rocha Fernandes, J.D., Ohlrogge, A.W. and B. Malanda. 2018. IDF Diabetes Atlas: Global estimates of diabetes prevalenve for 2017 and Projections for 2045, Diabetes Research and Clinical Practice, 138: 271-281.
Davies, M. J., David A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone. 2018. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia.
Decroli, E. 2019. Diabetes Melitus Tipe 2. Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas. Padang.
Dimic D., Golubovic M, Velojic., Radenkovic S., Radojkovic D. and Pasic M. 2016. The effect of metformin on THS levels in eythyroid and hypothyroid newly diagnosed diabetes mellitus type 2 patiens, Bratisl Med J. 2016. 117(8): 433-435.
Dinaryanti, P., Fundholi, A., & Andayani, T. M. (2012). Analisis Biaya dan Efektivitas Terapi Pasien Diabetes Melitus Tipe 2. Jurnal Manajemen Dan Pelayanan Farmasi, 2(1), 14–19.
Douros, A. et al. 2018. “Sulfonylureas as Second Line Drugs in Type 2 Diabetes and the Risk of Cardiovascular and Hypoglycaemic Events: Population Based Cohort Study.†BMJ (Online) 362.
Desi, W.N.E.R., dan Rd. Halim. 2018. Determinan Diabetes Mellitus Tipe 2 Di Kelurahan Talang Bakung Kota Jambi. Fakultas Kesehatan Masyarakat Universitas Jambi. Jurnal Kesmas Jambi (JKMJ) 50. Vol. 2, No. 1, Maret 2018.
Hemmingsen, B., Jeppe B.Schroll, Jorn Wetterslev, Christian Gluud, Allan Vaag, David P.Sonne, et al. 2014. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open, ;DOI:10.9778/cmajo.20130073.
Hestiana, D.W. 2017. Faktor – Faktor Yang Berhubungan Dengan Kepatuhan Dalam Pengelolaan Diet Pada Pasien Rawat Jalan Diabetes Mellitus Tipe 2 Di Kota Semarang. Jurusan Ilmu Kesehatan Masyarakat, Fakultas Ilmu Keolahragaan, Universitas Negeri Semarang, Indonesia. Jurnal of Health Education.
Isnaini, N., dan Ratnasari. 2018. Faktor risiko mempengaruhi kejadian Diabetes mellitus tipe dua. Departement of Nursing, Faculty of Health Science,
Universitas Muhammadiyah Purwokerto Jawa Tengah Indonesia. Jurnal Keperawatan dan Kebidanan Aisyiyah. Vol 14, No. 1, Juni 2018, pp.59-68.
J. Lyle Bootman, Raymond J. Townsend and William F. McGhan. 2004. Principles of Pharmacoeconomics - 3rd edition. Harvey Whitney Books Co.
Kemenkes RI. 2013. Riset Kesehatan Dasar, RISKESDAS. Jakarta: Badan Penelitian dan Pengembangan Kesehatan.
Kemenkes RI. 2018. Riset Kesehatan Dasar, RISKESDAS. Jakarta: Badan Penelitian dan Pengembangan Kesehatan.
Lee, J.H., Kim, J.H., A Ram Hong, Kim, S.W., Shin, C.S. 2020. Optimal body mass index for minimizing the risk for osteoporosis and type 2 diabetes. Korean J Intern Med. 35(6):1432-1442.
Lie, Putri G. C. E., Sylvi Irawati, Bobby Presley. 2016. Pencegahan Penyakit Kardiovaskular pada Pasien Diabetes Melitus Rawat Jalan: Fokus pada Penggunaan Antiplatelet, Statin dan Antihipertensi yang Belum Rasional. Fakultas Farmasi Universitas Surabaya, Surabaya, Indonesia. Jurnal Farmasi Klinik Indonesia, Juni 2016. Vol. 5 No. 3, hlm 169–183.
Lubis, M. A. dan Suprianto, 2018. Analisis Cost Effectivenees Penggunaan Antidiabetik Oral pada Pasien Diabetes Mellitus Tipe 2 Rawat Jalan Peserta BPJS di RSU Haji Medan. Institut Kesehatan Helvetia. Jalan Kapten Sumarsono, Np. 107, Medan, Indonesia. Volume 2, No.3, Agustus 2018 : 128-147.
Mihardja, L. 2009. Faktor yang Berhubungan dengan Pengendalian Gula Darah pada Penderita Diabetes Mellitus, Majalah Kedokteran Indonesia.Jakarta.
Mildawati, N.D., & Wahid, A. 2019. Hubungan Usia, Jenis Kelamin dan Lama Menderita Diabetes Dengan Kejadian Neuropati Perifer Diabetik.
Program Studi Ilmu Keperawatan Fakultas Kedokteran Universitas Lambung Mangkurat. Caring Nursing Journal. Vol. 3 No. 2 Oktober, 2019.
Musdalifah, P.S.N. 2020. Hubungan Jenis Kelamin dan Tingkat Ekonomi dengan Kejadian Diabetes Melitus di Wilayah Kerja Puskesmas Palaran Kota Samarinda Tahun 2019. Universitas Muhammadiyah Kalimantan Timur Samarinda Indonesia. Borneo Student Research eISSN: 2721-5725, Vol 1, No 2.
Paneni F, Beckman J, Creager M, Cosentino F. 2013. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part 1. Eur Heart J. 34(31):2436–43. doi: 10.1093/eurheartj/eht149.
Pambudi, D.B., Safitri, W.A., Muthoharoh, A. 2019. Potensi Penyakit Penyerta Pada Pengobatan Pasien Diabetes Mellitus Perspektif Terhadap Antidiabetik Oral. Sekolah Tinggi Ilmu Kesehatan Muhammadiyah Pekajangan Pekalongan. Jurnal Ilmiah Kesehatan (JIK) Vol XII, No II, September 2019.
Peraturan Menteri Kesehatan Nomor 27 Tahun 2014 Tentang Petunjuk
Teknis Sistem Indonesian Case Base Groups ( INA – CBGs ).
Rani, J., & Reddy, S. 2015. Prescribing Pattern Of Antidiabetic Drugs In Urban Population Of Hyderabad. National Journal of Physiology, Pharmacy & Pharmacology. Vol 5 Issue 1. Page 5–9.
Rodriguez, Joel, Saldana. 2019. Clinical Principles, Patient Management and Public Health Issues. Springer Nature Switzerland AG.
Romadhoni, H.A. 2018. Analisis Efektivitas Biaya Penggunaan Antara Metformin dan Glimepirid Pada Penderita Diabetes Mellitus Tipe 2 Rawat Jalan Di Rumah Sakit PKU Muhammadiyah Delanggu 2016. Fakultas Farmasi Universitas Muhammadiyah Surakarta.
Setiyorini, E., dan Wulandari, N.A.. 2017. Hubungan Lama Menderita Dan Kejadian Komplikasi Dengan Kualitas Hidup Lansia Penderita Diabetes Mellitus Tipe 2. Seminar Nasional dan Gelar Produk 17- 18 Oktober 2017. SENASPRO UMM.
Sharma, M., Nazareth, I., Petersen, I. 2016. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open;6:e010210.
Soedamah, M.SS., Fuller J.H., Mulnier, H.E., Raleigh, V.S., Lawrenson, R.A., Colhoun, H.M. 2006. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K. Diabetes Care. 29(4):798–804. doi: 10.2337/diacare.29.04.06.dc05-1433
Trisnawati, S.K., & Setyorono, S. 2013. Faktor Risiko Kejadian Diabetes Mellitus Tipe 2 di Puskesmas Kecamatan Cengkareng Jakarta Barat Tahun 2012. Jurnal Ilmiah Kesehatan, 5 (1): 1-11.
Taylor K, Heneghan C, Farmer A, Fuller AM, Adler AI, Aronson JK, et al. 2013. All cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. 36(8):2366–71. doi: 10.2337/dc12-1513 7.
Usman, J., Rahman, D., Rosdiana, Sulaiman, N. 2020. Faktor Yang Berhubungan Dengan Kejadian Diabetes Mellitus Pada Pasien Di RSUD Haji Makassar. Universitas Indonesia Timur. Jurnal Komunitas Kesehatan Masyarakat Volume 2 Nomor 1, Juli 2020 .
Wei, Wei, Changsheng Dou. 2019. Efficacy observation of metformin in the treatment of children with type II diabetes mellitus. Int J Clin Exp Med 12(10):12598-12604.
Yulianti, SR. Mukaddas, A. Faustine, I. 2012. Profil Pengobatan Pasien Diabetes Melitus tipe 2 di Instalasi Rawat Inap RSUD Undata Palu tahun 2012. Jurnal Of Natural Science, Vol. 3 No. 1 Maret:40-46.
Yuswantina, R. dan Dyahariesti, N. 2018. “Analisis Efektivitas Biaya Penggunaan Antidiabetes Oral Tunggal Dan Kombinasi Pada Pasien BPJS Penderita Diabetes Melitus Tipe 2 Di Rumah Sakit X.†Media Farmasi Indonesia 13(1): 1340–46.
Downloads
Published
Issue
Section
License
Authors who publish with Media Farmasi agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
This work is licensed under a Creative Commons Attribution 4.0 International License
